Cover Image

Not for Sale



View/Hide Left Panel

Herpesvirus varicellae

Attenuated live virus

Recipients of bone narrow and organ transplants and persons under age 25 with leukemias and lymphomas

558

337

320

237

372

231

219

162

 

 

Normal susceptibles, routine for children (booster for adults)

1391

1112

445

167

960

746

298

112

Influenza viruses A & B

Subunit vaccine (purified hemagglutinin/ neuramindase proteins)

High-risk population as currently defined (see Appendix K)

10644

9048

814

521

28225

23991

2159

1381

 

Attenuated live virus

High-risk population as currently defined

10644

9048

1357

504

28225

23991

3599

1336

Neisseria gonorrhoeae

A small number of promising options need investigation to determine best approach

Adolescents and adults age 15 and over

527

444

44

8

13811

(347)

11738

(294)

1174

(29.4)

201

(5)

Parainfluenza viruses

Trivalent, subunit vaccine (must contain fusion protein)

Infants

660

561

297

132

584

496

263

117

Respiratory Syncytial virus

Glycoprotein produced by recombinant DNA technology

Infants

3827

3062

980

458

3775

3020

966

452

 

Attenuated live virus

Infants

3827

3062

1623

759

3775

3020

1601

749

Rotavirus

Attenuated live bovine virus

Infants

281

253

68

41

227

204

55

33

 

Attenuated live human or reassortment virus

Infants

281

253

68

38

227

204

55

30

Streptococcus group B

Conjugated polysaccharide

Pregnant women for fetuses and neonates

3570

2856

314

125

3528

2823

311

124

aSee text and appendixes for explanation and derivation.

bAdjusted for vaccine efficacy; see text for explanation where efficacy varies with conditions.

cAdjusted for anticipated utilization.

dAdjusted for probability of success and time at which steady state of benefits would be achieved.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement